FDA grants Mavorixafor 'fast track title' for treatment of WHIM syndrome

WHIM syndrome is a rare, normal chromosomal-explicit genetic disorder that manifests it ite as warts, hypoproglobulinemia, bacterial infections, and an ineffective production of chronic granulocyte deficiency.
has now been shown to be associated with mutations in chemokine receptor 4 (CXCR4).
pharmaceutical company X4 Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has awarded Mavorixafor a "fast track title" for the treatment of adult patients with WHIM syndrome.
Mavorixafor, a CXCR4 small molecule antagonist, is currently in critical Phase III clinical trials around the world to treat WHIM syndrome.
Paula Ragan, President and CEO of X4 Pharmaceuticals, said: "WHIM syndrome is a serious disease whose disease mitigation therapy has not yet been met.
we recently demonstrated the potential therapeutic benefits of mavorixafor in a Phase II clinical trial, with a significant increase in white blood cell counts and a significant reduction in infection rates and wart loads.
look forward to continuing to demonstrate the clinical efficacy of mavorixafor in WHIM syndrome.
Our ongoing Phase III clinical trials have the potential to bring this promising treatment to patients as soon as possible."
.